Cidara Therapeutics

195 articles about Cidara Therapeutics

• Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018

  10/4/2018

  Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the presentation of data from the company’s Phase 2 STRIVE trial of rezafungin at IDWeek 2018, taking place in San Francisco from October 3-7.

• Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections

  9/27/2018

  Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.

• FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin Prophylaxis Development Program

  9/25/2018

  Cidara Therapeutics Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations for the company’s prophylaxis (prevention) development program for lead antifungal product candidate, rezafungin for injection.

• Mainstay Medical Announces the Appointment of Matthew Onaitis as Chief Financial Officer

  8/20/2018

  Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, announces the appointment of Matthew Onaitis as Chief Financial Officer, effective August 20, 2018.

• Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcoming Global Conferences

  6/15/2018

  Data Will Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections

• Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections

  5/21/2018

  ​New Partnership to Jointly Conduct Preclinical Development of Cidara’s Cloudbreak Antibody-Drug Conjugates

• Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting

  4/4/2018

  Company secures four oral presentations, including three that will highlight new data demonstrating activity of rezafungin against Candida auris and azole-resistant Aspergillus

• Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin

  3/19/2018

  Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported positive topline results from the global, randomized Phase 2 STRIVE clinical trial of its lead antifungal candidate rezafungin acetate.

• 

  Cidara Touts Positive Phase II Antifungal Data

  3/19/2018

  Cidara Therapeutics reported its mid-stage antifungal candidate hit its primary endpoints and is on track to begin Phase III testing later this year.
• 

  8 Biotech Companies with Upcoming Catalysts

  3/14/2018

  Here’s a look at eight biopharma companies with upcoming catalysts.

• Cidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 Meeting

  3/8/2018

  Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that two rezafungin abstracts...

• Cidara Therapeutics: Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections

  1/4/2018

  The papers reviews evidence and provides insights into the future of echinocandin therapy, including strategies for the treatment and prevention of life-threatening invasive fungal infections.

• Cidara Therapeutics Completes Enrollment in Phase II STRIVE Trial Evaluating Novel Antifungal Rezafungin (CD101 IV) in Invasive Fungal Infections

  11/28/2017

  Cidara expects to report topline data for STRIVE in the first quarter of 2018, and begin Phase 3 trials for the treatment and prophylaxis of invasive fungal infections in mid-2018.

• Cidara Provides Corporate Update and Reports Third Quarter 2017 Financial Results

  11/9/2017

  Conference call and webcast today at 1:05 p.m. PST/4:05 p.m. EST

• Cidara Therapeutics Announces Pricing of $20M Private Placement of Common Stock

  10/19/2017

  The company announced the pricing of a private placement of 3,360,000 shares of its common stock at a price of $6.00 per share.

• T2 Biosystems And Cidara Announce Partnership For Commercial Placement Of T2Dx Instruments To Support CD101 Drug Trials

  9/6/2017

• Cidara Provides Corporate Update And Reports Second Quarter 2017 Financial Results

  8/10/2017

• Cidara To Participate In Anti-Infectives Panel Discussion At The 2017 Infectious Diseases Summit

  7/6/2017

• Cidara To Participate In The 2017 BIO International Convention

  6/15/2017

• Cidara Joins SAFE-Biopharma Association

  5/31/2017